Clinical Trial Update: Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment [Phase 2]

View source ↗

Summary

The document notes that the Phase 2 trial of regorafenib to reduce recurrence in non-metastatic rectal cancer after curative treatment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma
• Rectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Rectal Adenocarcinoma, Stage IIA Rectal Cancer | Phase 2 | Status: WITHDRAWN